Pair page
Decapeptide-12 with Matrixyl
Mechanism-tag overlap and published literature for Decapeptide-12 and Matrixyl, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Decapeptide-12 unique
tyrosinase-inhibitor
Shared
cosmetic-peptide
Matrixyl unique
collagen-signal-peptide
Quick facts
Decapeptide-12
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient
WADAN/A (topical cosmetic)
Matrixyl
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient (not a drug)
WADAN/A (topical cosmetic)
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2018 | Decapeptide-12 | Jiang L, Hino PD, Bhatia A, Stephens TJ, Jimenez F. Efficacy of Trifecting Night Cream, a novel triple-acting skin brightening product: a double-blind, placebo-controlled clinical study. J Clin Aesthet Dermatol. 2018;11(12):25-30. (Envy Medical triple-action cream containing dec… | human trial |
| 2009 | Decapeptide-12 | Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol. 2009;8(8):732-735. PMID: 19663110. (Pivotal split-face RCT pilot in five Fitzpatrick IV fema… PMID 19663110 | human trial |
| 2013 | Decapeptide-12 | Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, Flórez AM, Echeverry HF. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma. J Drugs Dermato… PMID 23839199 | human pilot |
| 2012 | Decapeptide-12 | Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. J Drugs Dermatol. 2012;11(5):660-662. PMID: 22527440. (Open-label evaluation of the full Lumixyl brightening system in mild-to-moderate facial melasma.) PMID 22527440 | human pilot |
| 2012 | Decapeptide-12 | Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12 (24-week photodamage study). J Drugs Dermatol. 2012. PMID: 22401652. (24-week open-label in photodamaged facial hyperpigmentation; subset-shift improvements in grade-4 severe… PMID 22401652 | human pilot |
| 2012 | Decapeptide-12 | Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg. 2012;38(7 Pt 1):971-984. PMID: 22583339. (Hantash-co-authored contemporary melasma-therapeutics review that situates decapeptide-12 within the broader depigmentin… PMID 22583339 | human study |
| 2019 | Decapeptide-12 | Hantash BM, Abu Ubeid A. Tyrosinase inhibitors with potent anti-senescence activity in human neonatal keratinocyte progenitors. 2019. (Extends decapeptide-12 mechanistic claims into SIRT-pathway anti-senescence in human keratinocytes — supports "brightening plus anti-aging" posi… | preclinical, in vitro |
| 2009 | Decapeptide-12 | Abu Ubeid A, Zhao L, Wang Y, Hantash BM. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol. 2009;129(9):2242-2249. PMID: 19440221. (Foundational discovery paper — phage-display biopanning that identified decapeptide-12… PMID 19440221 | preclinical, in vitro |
| 1993 | Decapeptide-12 | Iozumi K, Hoganson GE, Pennella R, Everett MA, Fuller BB. Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol. 1993;100(6):806-811. (Classic determinant-of-pigmentation paper establishing tyrosinase as the rate-limiting enzyme o… | preclinical, in vitro |
| 2016 | Decapeptide-12 | Ochiai A, Tanaka S, Tanaka T, Taniguchi M. New tyrosinase inhibitory decapeptide: molecular insights into the role of tyrosine residues. J Biosci Bioeng. 2016;121(6):607-613. (Independent decapeptide-class tyrosinase-inhibitor work highlighting the role of tyrosine residues in t… | mechanism / discovery |
| 2012 | Decapeptide-12 | Ubeid AA, Do S, Nye C, Hantash BM. Potent low toxicity inhibition of human melanogenesis by novel indole-containing octapeptides. Biochim Biophys Acta. 2012;1820(10):1481-1489. (Extended structure-activity work from the Hantash group on the peptide-tyrosinase inhibitor scaffold.) | mechanism / discovery |
| 2014 | Decapeptide-12 | Ubeid AA, Hantash BM. Minireview: Peptide analogs and short sequence oligopeptides as modulators of skin pigmentation. Curr Top Med Chem. 2014;14(12):1418-1424. PMID: 24894693. (Review of tyrosinase-inhibitor oligopeptides and α-MSH analogs in cosmetic and dermatologic pigment m… PMID 24894693 | review |
| 2009 | Matrixyl | Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. PMID: 19570099. (UCSF Dermatology systematic review of topical peptides for aged skin, including Pal-KTTKS signal-peptide class.) PMID 19570099 | systematic review |
| 2010 | Matrixyl | Fu JJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, Grimes PE, Mandy SH, Perez MI, Weinkle SH, Kaczvinsky JR. A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescri… PMID 20374604 | human trial |
| 2024 | Matrixyl | Vitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization. Pharmaceutics. 2024;16(2):219. PMID: 38399273. (Liposomal delivery system for Pal-KTTKS… PMID 38399273 | preclinical, in vitro |
| 2017 | Matrixyl | Park H, An E, Cho Lee AR. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression. Tissue Eng Regen Med. 2017;14(1):73-80. PMID: 30603464. (CTGF / α-SMA modulation and fibrobl… PMID 30603464 | preclinical, in vitro |
| 2014 | Matrixyl | Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-327. PMID: 25143811. (Demonstrates palmitoylation as stability and permeation enhancer relative to un… PMID 25143811 | preclinical, in vitro |
| 2013 | Matrixyl | Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol Pharm. 2013;10(3):1063-1069. PMID: 23320752. (Direct fibroblast collagen-production dose-response for Pal-KTTKS linked to critical-aggregation-con… PMID 23320752 | preclinical, in vitro |
| 2019 | Matrixyl | Tałałaj U, Uscinowicz P, Bruzgo I, Surazynski A, Zareba I, Markowska A. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. Molecules. 2019;24(20):3698. PMID: 31618846. (Structure-activity series of KTTKS analogues with acetyl / lipoyl / pa… PMID 31618846 | mechanism / discovery |
| 2019 | Matrixyl | Mortazavi SM, Kobarfard F, Maibach HI, Moghimi HR. Effect of Palmitic Acid Conjugation on Physicochemical Properties of Peptide KTTKS: A Preformulation Study. J Cosmet Sci. 2019;70(6):299-312. PMID: 31829923. (Physicochemical characterization of palmitoyl conjugation effects on… PMID 31829923 | mechanism / discovery |
| 2007 | Matrixyl | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. PMID: 18045359. (Updated Dermatologic Therapy review of signal, neurotransmitter-affecting, and carrier peptides.) PMID 18045359 | review |
| 2005 | Matrixyl | Osborne R, Mullins L, Jarrold B, Lintner K. In vitro skin structure benefits with a new antiaging peptide, Pal-KT. J Am Acad Dermatol. 2005;52(3 Suppl):P34. (AAD-meeting abstract on Pal-KT / Pal-KTTKS cosmetic evaluation; Procter & Gamble / Sederma collaboration.) | industry documentation |
| 2009 | Matrixyl | Trookman NS, Rizer RL, Ford R, Ho E, Gotz V. Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles. J Clin Aesthet Dermatol. 2009;2(3):38-43. PMID: 20729942. (8-week topical treatment clinical study including palmitoyl pentapeptide active… PMID 20729942 | research article |
| 2005 | Matrixyl | Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID: 18492182. (The 93-subject 12-week split-face vehicle-controlled RCT of 3 ppm Pa… PMID 18492182 | research article |
Related pair pages
More research context
Frequently asked
Have Decapeptide-12 and Matrixyl been studied together?
No co-administration studies between Decapeptide-12 and Matrixyl are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Decapeptide-12 and Matrixyl share?
Decapeptide-12 and Matrixyl share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Decapeptide-12 and Matrixyl?
Decapeptide-12: Cosmetic ingredient. Matrixyl: Cosmetic ingredient (not a drug). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Decapeptide-12 and Matrixyl?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Decapeptide-12 profile and the Matrixyl profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026